The last bit of exempt distribution funding RVX took in is $176K US in May 2023. And a loan from Zenith in the second quarter of 2023, in the amount of ~$1.5 Million US. I would say by now RVX has depleted all this cash. 

Zenith needs to bear some serious fruit from ZEN-3694 in their collaboration on several ongoing fronts (Clinical Trials) that are barely past a Phase 2 timeline with Big Pharma to come to the salvation of RVX to cement what we were told at the AGM.

RVX needs a third major equity partner for an immediate large cash infusion to maintain its operations and to get BOM2 going. The share price of 6.5 cents CAN may make this difficult without giving away majority ownership to a third major equity partner.   

Koo (IMO)